Mike Kratky
Stock Analyst at Leerink Partners
(4.71)
# 189
Out of 4,413 analysts
26
Total ratings
68.75%
Success rate
37.41%
Average return
Main Sectors:
Top Industries:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $36.20 | +24.31% | 2 | Apr 25, 2024 | |
| SWAV ShockWave Medical | Downgrades: Market Perform | $361 → $335 | $329.84 | +1.56% | 2 | Apr 8, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $13.97 | +57.48% | 1 | Jan 30, 2024 | |
| AXNX Axonics | Downgrades: Market Perform | $71 | $66.87 | +6.18% | 2 | Jan 12, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $170.27 | +8.06% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $47.08 | -10.79% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $371.70 | -7.99% | 1 | Oct 16, 2023 | |
| INSP Inspire Medical Systems | Initiates: Market Perform | $159 | $244.00 | -34.84% | 1 | Oct 16, 2023 | |
| EW Edwards Lifesciences | Initiates: Market Perform | $75 | $84.30 | -11.03% | 1 | Oct 16, 2023 | |
| DXCM DexCom | Initiates: Outperform | $110 | $125.88 | -12.62% | 1 | Oct 16, 2023 | |
| PRCT PROCEPT BioRobotics | Initiates: Outperform | $37 | $60.61 | -38.95% | 1 | Oct 16, 2023 | |
| AXGN AxoGen | Initiates: Outperform | $9 | $6.56 | +37.20% | 1 | Oct 16, 2023 | |
| GLTO Galecto | Downgrades: Market Perform | $13 → $2 | $0.68 | +194.07% | 2 | Aug 15, 2023 | |
| PLRX Pliant Therapeutics | Maintains: Outperform | $33 → $45 | $12.66 | +255.45% | 2 | Jan 24, 2023 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $145 → $315 | $210.59 | +49.58% | 1 | Dec 20, 2022 | |
| KYMR Kymera Therapeutics | Maintains: Market Perform | $26 → $31 | $36.24 | -14.46% | 2 | Dec 15, 2022 | |
| IMVT Immunovant | Maintains: Outperform | $12 → $14 | $28.52 | -50.91% | 1 | Nov 4, 2022 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $40 | $13.81 | +189.65% | 1 | Aug 15, 2022 | |
| RAPT RAPT Therapeutics | Maintains: Outperform | $49 → $48 | $8.18 | +486.80% | 1 | Aug 11, 2022 | |
| MORF Morphic Holding | Initiates: Outperform | $45 | $27.97 | +60.89% | 1 | Jul 20, 2022 |
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $36.20
Upside: +24.31%
ShockWave Medical
Apr 8, 2024
Downgrades: Market Perform
Price Target: $361 → $335
Current: $329.84
Upside: +1.56%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $13.97
Upside: +57.48%
Axonics
Jan 12, 2024
Downgrades: Market Perform
Price Target: $71
Current: $66.87
Upside: +6.18%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $170.27
Upside: +8.06%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $47.08
Upside: -10.79%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $371.70
Upside: -7.99%
Inspire Medical Systems
Oct 16, 2023
Initiates: Market Perform
Price Target: $159
Current: $244.00
Upside: -34.84%
Edwards Lifesciences
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $84.30
Upside: -11.03%
DexCom
Oct 16, 2023
Initiates: Outperform
Price Target: $110
Current: $125.88
Upside: -12.62%
PROCEPT BioRobotics
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $60.61
Upside: -38.95%
AxoGen
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $6.56
Upside: +37.20%
Galecto
Aug 15, 2023
Downgrades: Market Perform
Price Target: $13 → $2
Current: $0.68
Upside: +194.07%
Pliant Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $12.66
Upside: +255.45%
Madrigal Pharmaceuticals
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $210.59
Upside: +49.58%
Kymera Therapeutics
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $36.24
Upside: -14.46%
Immunovant
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $28.52
Upside: -50.91%
Viridian Therapeutics
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $13.81
Upside: +189.65%
RAPT Therapeutics
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $8.18
Upside: +486.80%
Morphic Holding
Jul 20, 2022
Initiates: Outperform
Price Target: $45
Current: $27.97
Upside: +60.89%